Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

pSivida and Nicox inks deal to develop sustained release drug to lower IOP in patients with Glaucoma; shares ahead 12% premarket

Published 10/10/2017, 07:48 AM
© Reuters.  pSivida and Nicox inks deal to develop sustained release drug to lower IOP in patients with Glaucoma; shares ahead 12% premarket
EYPT
-
  • pSivida (NASDAQ:PSDV) and Nicox S.A. (OTCPK:NICXF) collaborate to explore the potential of combining pSivida's bioerodible sustained release drug delivery system with Nicox's nitric oxide-donating compounds, to develop a sustained release drug to lower intraocular pressure in patients with glaucoma or ocular hypertension.
  • pSivida will be responsible for initial development activities of ocular insert formulations, for which it will receive undisclosed sums by Nicox.
  • Nicox would make additional payments for any incremental development activities. New intellectual property from the collaboration will be jointly owned. Separate license agreement will be negotiated for any product candidate, developed and commercialize as a result of this collaboration.
  • Shares of pSivida are ahead 12% premarket on modest volume.
  • Now read: uniQure: A Busted Biotech IPO Worth Owning


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.